Orion PharmaDHA:ORIONPHARM +0.35%69 Days Inventory is 129.38 as of Mar. 2026, which is 110% above its 10-year median of 61.52. GuruFocus rates DHA:ORIONPHARM with a GF Score™ of 69/100 and a GF Value™ of BDT20.31 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 332 Utilities - Independent Power Producers companies, Orion Pharma ranks worse than 89.16% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Orion Pharma's Average Total Inventories for the
three
months ended in Mar. 2026 was BDT1,221 Mil. Orion Pharma's Cost of Goods Sold for the
three
months ended in Mar. 2026 was BDT861 Mil.
Hence, Orion Pharma's Days Inventory for the
three
months ended in Mar. 2026 was 129.38.
The historical rank and industry rank for Orion Pharma's Days Inventory or its related term are showing as below:
DHA:ORIONPHARM'
s Days Inventory Range Over the Past 10 Years
Min: 20.5 Med: 61.52 Max: 223.14
Current: 223.14
During the past 12 years, Orion Pharma's highest Days Inventory was 223.14. The lowest was 20.50. And the median was 61.52.
DHA:ORIONPHARM's Days Inventory is ranked worse than 89.16% of 332
companies
in the Utilities - Independent Power Producers industry
Industry Median: 28.77
vs DHA:ORIONPHARM: 223.14
Orion Pharma's Days Inventory
declined
from Mar. 2025 (341.33) to Mar. 2026 (129.38).
Warning Sign:
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Orion Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.71.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orion Pharma's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.82.
Orion Pharma (DHA:ORIONPHARM) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Orion Pharma's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orion Pharma's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Orion Pharma Days Inventory Related Terms
Orion Pharma Days Inventory Historical Data
* Premium members only.
The historical data trend for Orion Pharma's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DHA:ORIONPHARM vs CEG, VST, NRG: Days Inventory Comparison
For the Utilities - Independent Power Producers subindustry, Orion Pharma's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orion Pharma Days Inventory vs Utilities - Independent Power Producers Industry
For the Utilities - Independent Power Producers industry and Utilities sector, Orion Pharma's Days Inventory distribution charts can be found below:
* The bar in red indicates where Orion Pharma's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orion Pharma (DHA:ORIONPHARM) has a Days Inventory of 129.38 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Orion Pharma and its competitors. This is 110% above median its historical median of 61.52. Over the past decade, Orion Pharma's Days Inventory has ranged from 20.50 to 223.14. According to the industry distribution chart, Orion Pharma ranks #296 out of 332 companies in the Utilities - Independent Power Producers industry, placing it in the top 89.2%.
Is Orion Pharma's Days Inventory too high?
Orion Pharma's current Days Inventory of 129.38 is 110% above median its 10-year median of 61.52. Over the past 10 years, this metric has ranged from a low of 20.50 to a high of 223.14. The Utilities - Independent Power Producers industry median Days Inventory is 28.77. Orion Pharma's value of 129.38 is 349.7% above this industry median. Based on the distribution chart, Orion Pharma ranks #296 out of 332 companies in the Utilities - Independent Power Producers industry, which is in the bottom quartile relative to peers. Overall, Orion Pharma has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Orion Pharma's Days Inventory compare to CEG and VST?
According to the Utilities - Independent Power Producers industry distribution chart, Orion Pharma ranks #296 out of 332 companies for Days Inventory. This places Orion Pharma in the lower half of its industry. The industry median Days Inventory is 28.77. Orion Pharma's value of 129.38 is 349.7% above this benchmark. Historically, Orion Pharma's own Days Inventory has ranged from 20.50 to 223.14 over the past decade. While the company's 10-year median is 61.52 vs. the industry median of 28.77, Orion Pharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for an Utilities - Independent Power Producers company?
The median Days Inventory among Utilities - Independent Power Producers companies is 28.77, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orion Pharma's current Days Inventory of 129.38 is 349.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Orion Pharma and its competitors. For the Utilities - Independent Power Producers industry, the median Days Inventory is 28.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orion Pharma's current Days Inventory is 129.38, which is 110% above median its own 10-year median of 61.52. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orion Pharma stock overvalued right now?
Based on GuruFocus' analysis, Orion Pharma (DHA:ORIONPHARM) is currently considered Significantly Overvalued. The stock's GF Value™ is BDT20.31, compared to a current price of BDT28.60 — trading 40.8% above its estimated fair value. The current Days Inventory is 129.38, which is 110% above median its 10-year median of 61.52 and 349.7% above the Utilities - Independent Power Producers industry median of 28.77. Orion Pharma's overall GF Score™ is 69/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Orion Pharma (DHA:ORIONPHARM), the current Days Inventory is 129.38 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orion Pharma (DHA:ORIONPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Orion Pharma stock appears to be overvalued.
The current stock price of BDT28.60 is trading 40.8% above its estimated GF Value™ of BDT20.31.
GuruFocus considers Orion Pharma to be Significantly Overvalued.
Key valuation signals for DHA:ORIONPHARM:
Days Inventory: 129.38 (110% above median its 10-year median of 61.52)
GF Value™: BDT20.31 vs. price of BDT28.60 (40.8% above fair value)
Industry Position: 349.7% above the Utilities - Independent Power Producers median (#296 of 332)
No single metric tells the full story. See the DHA:ORIONPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orion Pharma Ltd is a pharmaceutical company engaged in the creation and discovery, development, manufacturing, and marketing of pharmaceutical products, including vaccines and health-related consumer products. The company produces diversified dosage forms such as tablets, capsules, syrups, solutions, suspensions, powder for suspensions, creams, ointments, and injections under therapeutic categories including cardiovascular, antiulcerant, antiasthmatic, antihistamine, NSAIDs, antibiotic, antifungal, laxatives, anticancer, vitamins, and minerals. In addition, the company is involved in power generation activities and generates maximum revenue from pharmaceutical activities. The group principally carries out its business operations and markets its products in Bangladesh.
69GF Score
Get the complete analysis for DHA:ORIONPHARM
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DHA:ORIONPHARM has been successfully added to your 
